No Data
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma
Express News | Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as Uva Cancer Center Doses Its First Patient
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as UVA Cancer Center Doses Its First Patient
US Manufacturing Index Rises To 43, Highest Since 2020
Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY
Shuttle Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
No Data